LLY

1,135.81

-0.49%↓

JNJ

238.82

+1.16%↑

ABBV

225.92

+0.44%↑

UNH

405.52

-1.41%↓

MRK

117.87

-1.43%↓

LLY

1,135.81

-0.49%↓

JNJ

238.82

+1.16%↑

ABBV

225.92

+0.44%↑

UNH

405.52

-1.41%↓

MRK

117.87

-1.43%↓

LLY

1,135.81

-0.49%↓

JNJ

238.82

+1.16%↑

ABBV

225.92

+0.44%↑

UNH

405.52

-1.41%↓

MRK

117.87

-1.43%↓

LLY

1,135.81

-0.49%↓

JNJ

238.82

+1.16%↑

ABBV

225.92

+0.44%↑

UNH

405.52

-1.41%↓

MRK

117.87

-1.43%↓

LLY

1,135.81

-0.49%↓

JNJ

238.82

+1.16%↑

ABBV

225.92

+0.44%↑

UNH

405.52

-1.41%↓

MRK

117.87

-1.43%↓

Home・Aktien・CareDx Inc

CareDx Inc

Open

BrancheGesundheitswesen

23.23 4.97

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

22.29

Max

23.26

Schlüsselkennzahlen
By Trading Economics
Einkommen	6.9M 2.8M
Verkäufe	9.3M 118M
KGV Branchendurchschnitt	14.645 49.052
EPS	0.34
Gewinnspanne	2.387
Angestellte	761
EBITDA	5.6M 7.1M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+23.08% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	5. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	15M 1.1B
Vorheriger Eröffnungskurs	18.26
Vorheriger Schlusskurs	23.23

Nachrichtenstimmung

By Acuity

38%

62%

113 / 344 Ranking in Healthcare

CareDx Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

CareDx Inc Prognose

Kursziel

By TipRanks

23.08% Vorteil

12-Monats-Prognose

Durchschnitt 28 USD 23.08%

Hoch 28 USD

Tief 28 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für CareDx Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

5 ratings

Buy

Halten

Sell

Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für CareDx Inc – Dist abgegeben haben.

Stimmung

By Acuity

113 / 344 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.